Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Scottish Medicines Consortium ACCEPTS AMGEN’S Multiple Myeloma Treatment, kyprolis® (carfilzomib), in combination with Dexamethasone, for use at first relapse

Scottish Medicines Consortium
Posted on: 08 Aug 17

·        Carfilzomib Accepted in Combination with Dexamethasone Alone for the Treatment of Adult Patients with Multiple Myeloma who have Received At least One Prior Therapy

·        Patients Treated with Carfilzomib in Combination with Dexamethasone Showed a Significant Increase in Progression-Free Survival Compared to Bortezomib with Dexamethasone

·        Carfilzomib is the First and Only Proteasome Inhibitor to Demonstrate Statistically Significant Improved Overall Survival in a Head-to-Head Trial


Cambridge, UK (7 August 2017) – Today, the Scottish Medicines Consortium (SMC) has published its advice accepting the use of KYPROLIS (carfilzomib) in combination with dexamethasone alone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. The advice takes into account the continuing availability of the Patient Access Scheme (PAS) agreed or a list price that is equivalent or lower.[1]


The SMC advice guides NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on the use of carfilzomib within NHS Scotland. It has taken into account the views of patient group representatives and clinical specialists in a Patient and Clinical Engagement (PACE) meeting.1


“This is great news for patients in Scotland. The approval of carfilzomib and dexamethasone for use on the NHS gives myeloma patients, whose cancer has come back, an important new treatment option,” said Shelagh McKinlay, Policy and Public Affairs Officer, Myeloma UK. “We are especially pleased that the approval covers all patients who have had one prior treatment as carfilzomib and dexamethasone has been shown to be very effective in prolonging survival in relapsed myeloma patients, and should be available to doctors as a prescribing option for their eligible patients.”


Clinical experts consulted by the SMC considered that carfilzomib plus dexamethasone is a therapeutic advance as it provides an opportunity to increase overall and progression-free survival when compared to bortezomib plus dexamethasone; one of the current standard of care for relapsed multiple myeloma. It also concluded that carfilzomib is associated with a reduced rate of peripheral neuropathy.1


The key evidence to support the use of carfilzomib in combination with dexamethasone in the treatment of adults with relapsed multiple myeloma was based on the large Phase 3 randomised study, ENDEAVOR (n=929). This first ever head-to-head clinical trial, comparing two proteasome inhibitors, showed that adults treated with carfilzomib plus dexamethasone lived almost twice as long without their cancer progressing (progression-free survival; PFS) compared to bortezomib plus dexamethasone (18.7 months vs. 9.4 months).[2] Moreover, in a planned interim analysis of overall survival (OS), carfilzomib and dexamethasone (Kd) reduced the risk of death by 21 percent compared to bortezomib and dexamethasone (Vd), resulting in a 7.6 month survival benefit (median OS 47.6 months for Kd versus 40.0 for Vd, HR=0.79; 95 percent CI: 0.65 – 0.96; p=0.01).[3]


“We are pleased with the outcome from the Scottish Medicines Consortium, which follows the recent National Institute for Health and Care Excellence’s recommendation for carfilzomib. This means that suitable patients in England, Wales and Scotland will have access to a treatment with proven evidence to prolong progression-free and overall survival,” said Tony Patrikios, Executive Medical Director at Amgen UK and Ireland. “We know that time free of disease is precious and we are committed to advancing care for people with this difficult-to-treat blood cancer. We see carfilzomib as the backbone therapy for the management of relapsed multiple myeloma.”


In the UK, it is estimated that there are approximately 17,500 people living with myeloma[4] and it accounts for around two percent of all cancers.4 In Scotland, it is estimated that there are 473 new cases and 273 deaths due to multiple myeloma each year.[5] It is estimated that over 1,300 patients will be eligible for treatment rising to over 1,700 patients by year five.1


Following the publication of the SMC’s advice, NHS Boards in Scotland now have a maximum of 60 days to include carfilzomib in their formularies for the treatment of patients with multiple myeloma who have received at least one prior therapy. The advice is contingent upon Amgen UK providing carfilzomib to NHS Scotland within the terms of the agreed PAS.

Editor's Details

Mike Wood

Last updated on: 08/08/2017

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.